Joint Development Team. Upon initiation of the Feasibility Program, the parties shall establish a joint development team (the “Joint Development Team”) which shall consist of two (2) representatives appointed by each party. The chairperson of the Joint Development Team shall be a representative of Voyager (the “Chair”). Each party may, from time to time, change one or more of its representatives by written notice to the other party. The Joint Development Team shall be responsible for and establish procedures for the management of the Feasibility and Development Programs in accordance with the Feasibility and Development Plans and shall serve as points of contact between the parties to coordinate activities and ensure that the parties perform their respective obligations (if any) diligently in accordance with the Feasibility Plan and the Development Plan. The Joint Development Team shall meet at least once per month (either by telephone or in person, as agreed to by SBS and Voyager) to review the planning and the progress of the Feasibility and Development Programs and to consider recommendations regarding, and to make changes to, the Feasibility and Development Plans and performance of the Feasibility and Development Programs. In performing its functions, the Joint Development Team shall attempt to reach all decisions by consensus. However, if the members cannot reach consensus with respect to any decision within a reasonable time period (which shall not be more than thirty (30) days) after careful consideration, the matter shall be referred to the chief executive officers of Voyager and SBS for review and discussion. In the event the CEOs of Voyager and SBS cannot reach agreement within a reasonable time period (which shall not be more than thirty (30) days), then the Chair shall make the final decision, which shall be final and binding on the parties. Notwithstanding the foregoing, nothing herein, and no decision made under this Section, shall be deemed to modify or supersede the express terms or conditions of this Agreement, or any decision or decision-making authority otherwise expressly provided for in this Agreement.
Joint Development Team. Cadence and the Partnership will jointly manage the activities undertaken pursuant to this Agreement through the Joint Development Team.
(a) The JDT will consist of three representatives of each of Cadence and the Partnership. One representative, the JDT Manager, shall be a senior executive of the assigning party. The second member of the JDT, the JDT Technical Lead, shall be a person of technical background and responsibilities. The third member of the JDT, the JDT Finance Lead, shall be a person of finance background and responsibilities. Either Party may change its designees on the JDT at any time and from time to time upon written notice to the other Party.
(b) The JDT shall conduct regular meetings, to be conducted at least quarterly, and more frequently, if reasonably requested by either JDT Manager. Each such meeting shall be convened after prior written notice has been provided to each member, unless otherwise agreed in writing by both parties. Each such notice shall set out the agenda for the meeting in sufficient detail to allow each party to prepare adequately therefore. Meetings of the JDT may be held in person, by teleconference, or by videoconference.
(c) The JDT acts by consensus as to Methodology Technology Development and, accordingly, neither Party is obligated to perform or accept, or pay for or incur costs, for any Project, task or other assignment, where not approved by the JDT or, in its stead, both the Cadence and the Partnership JDT Manager. In the event of a deadlock regarding any JDT decision-making, either party shall have the option to refer the deadlocked matter to the Sponsoring Executives for resolution. In addition, the JDT and the Sponsoring Executives will attempt to resolve any disputes between Cadence and Tality arising out of or in connection with this Agreement. Where the JDT is unable to resolve a disagreement or dispute, the matter will be submitted to the Sponsoring Executives, who shall then meet and fully discuss such dispute in an attempt to achieve its prompt resolution.
(d) The JDT will execute the JDP by preparation, approval, funding, oversight and management of MTD Projects, inclusive of Deliverables, Statements Of Work, budgets, specifications, schedules and such other elements of performance as the JDT may determine. The JDT shall review the key resources each performing party intends to assign to Projects. The JDT shall oversee the preparation of a mutually satisfactory means to account for costs expended...
Joint Development Team. The parties will form a Joint Development Team (the “JDT”). The JDT will meet on a schedule to be determined by the parties but not less than twice yearly and will be responsible for facilitating the exchange of preclinical data, clinical data, information, materials and results between Sublicensor and Sublicensee and for consulting on the regulatory development of Product in the Sublicense Territory, including regulatory filings relating to manufacture of Product for the Sublicense Territory and consultation as to changes in specifications or other changes for Product in the Sublicense Territory. As of the Effective Date, the parties agree that participation on, and any duties associated with, the JDT shall be voluntary, and no penalty under this Agreement shall apply for non-participation.
Joint Development Team. ASLAN and CSL shall establish a joint development committee (“Joint Development Team” or “JDT”) to oversee the execution of the Development and Development Program during the Term. From time to time, the JDT may establish subcommittees or project teams to oversee particular projects or activities, and such subcommittees or project teams will be constituted as the JDT agrees (e.g., for oversight of certain day-to-day matters).
Joint Development Team. Concurrently with the establishment of the Joint Steering Committee or as soon as possible after an additional Collaboration Product has been selected by the Joint Research Committee pursuant to Section 2.10, as applicable, on a Collaboration Product-by-Collaboration Product basis, the Parties shall – on a project level – establish a joint development team, to coordinate and implement all activities for the Development of a Collaboration Product according to the Joint Development Plan (the Joint Development Team). One representative from each Party shall be designated as that Party’s Development Project Manager to act as the primary Joint Development Team contact for that Party. The Joint Development Team shall consist of such number of representatives of each Party as are reasonably necessary to accomplish the goals of the Joint Development Team hereunder. Either Party may replace any or all of its representatives at any time upon notice to the other Party
Joint Development Team. The parties will form a Joint Development Team (the “JDT”). The JDT will meet on a schedule to be determined by the parties but not less than twice yearly and will be responsible for facilitating the exchange of preclinical data, clinical data, information, materials and results between Sublicensor and Sublicensee and for consulting on the regulatory development of Product in the Sublicense Territory, including regulatory filings relating to manufacture of Product for the Sublicense Territory and consultation as to changes in specifications or other changes for Product in the Sublicense Territory.
Joint Development Team. Concurrently with the establishment of the Joint Steering Committee or as soon as possible after an additional LCA Product has been selected by the Joint Research Committee pursuant to Section 2.10, as applicable, on an LCA Product-by-LCA Product basis, the Parties shall – on a project level – establish a joint development team, to monitor, coordinate and implement all activities for the Development of an LCA Product according to the Development Plan (the Joint Development Team). The Joint Development Team shall consist of such number of representatives of each Party as are reasonably necessary to accomplish the goals of the Joint Development Team hereunder. Either Party may replace any or all of its representatives at any time upon notice to the other Party
Joint Development Team. 15 2.1 Establishment of Joint Development Team.................................... 15 2.2 Responsibilities of the Joint Development Team............................. 16 2.3 Meetings; Minutes.......................................................... 16 2.4 Decision-Making and Dispute Resolution..................................... 17 2.5 Expenses................................................................... 17 2.6
Joint Development Team. Within [*] after the Effective Date, the Parties shall establish a joint development team (the “Joint Development Team” or the “JDT”), composed of two (2) to three (3) representatives of each Party that have knowledge and expertise in the development of compounds similar to the Compounds, [*], to monitor the Development of NLG919 Products, Next Generation Products, and NewLink Combination Therapies. The role of the JDT shall be to monitor and discuss the Development of such products and therapies.
Joint Development Team. Promptly after the Effective Date, the JSC will establish a Joint Development Team ("JDT"), which shall include, at Vertex's option, [***]. During the course of the Development Program, GSK shall provide the JDT (or Vertex, if Vertex has no representative on the JDT or the JSC) at least every [***] with the planning information listed under "Development" and "CMC" on Schedule 3.3, in GKS's standard format, as and when that information is generated and becomes available within GSK, updated to reflect ongoing activities. GSK will also provide summaries of results of all non-clinical and clinical trials. One purpose of the information is to allow the JDT (or Vertex) to review the progress and anticipated direction of the Development Program, propose amendments, where appropriate, to the Development Plan and provide comments for consideration regarding the future direction of the Development Program. Consequently information will be supplied to the JDT (or Vertex) at a time sufficiently prior to finalization of each Development Plan to accommodate any suggestions and comments by Vertex which are deemed by GSK, in its sole discretion, to be worth incorporating in the planning process for each Product Candidate and Product. Following any Product Candidate entering into Phase III Clinical Trials, GSK shall provide the JDT at least every [***] with the planning information listed under "Commercialization" on Schedule 3.3, in GSK's standard format, as and when that information is generated and becomes available within GSK, updated to reflect ongoing activities, so that the JDT can review the preparation and implementation of the Global Marketing Plan and where appropriate propose for consideration amendments to it. For the avoidance of doubt, the JDT shall act in an advisory capacity only and shall have no authority to require any amendments to either the Development Plan or the Global Marketing Plan. During the Term, the Joint Development Team shall meet quarterly, or as otherwise agreed by the Parties, either in person or by teleconference or by videoconference, on such dates and at times as the Parties shall agree. Meetings of the JDT that are held in person shall alternate between the offices of the Parties, or such other places as the Parties may agree. Each party will be responsible for its representatives' expenses incurred in attending meetings of the JDT. If at any time, Vertex is not represented at any JDT meeting by at least [***]. GSK may thereafter sus...
